A nitrogen-containing compound is represented by the following Formula 1 ##STR00001##
where B.sub.1 to B.sub.4 are each independently N or CR.sub.1, A.sub.1 is an electron accepting group, L1 and R1 are further defined, and D is an electron donating group represented by the following Formula 2 ##STR00002##
X is Si or Ge and Y1, Y2, R2, R3, n and m are further defined. An organic electroluminescence device includes the nitrogen-containing compound.

The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

A light emitting element that includes a first electrode, a second electrode facing the first electrode, and an emission layer between the first electrode and the second electrode is provided. The emission layer includes a polycyclic compound represented by Formula 1. The light emitting element has a reduced driving voltage and an increased efficiency.

##STR00001##

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

This invention discloses oligosilane compounds. These compounds can be used in OLEDs.

Provided are a condensed cyclic compound and an organic light-emitting device including the same. The organic light-emitting device may include a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode. The organic layer may include the condensed cyclic compound represented by Formula 1: ##STR00001## In Formula 1, rings A.sub.1, A.sub.2, and A.sub.3 may each be independently a C.sub.5-C.sub.60 carbocyclic group or a C.sub.2-C.sub.30 heterocyclic group, and n1 to n3 may each be independently 0 or 1, provided that the sum of n1, n2, and n3 is 1. In addition, the descriptions of X.sub.1, L.sub.1 to L.sub.9, a1 to a9, Ar.sub.1 to Ar.sub.6, b1 to b6, R.sub.1 to R.sub.3, and c1 to c3 are as defined in the present specification.

The present specification relates to an organic light emitting device comprising a first electrode, a second electrode, and an organic material layer comprising one or more layers provided between the first electrode and the second electrode, wherein the one or more layers of the organic material layer comprise a heterocyclic compound represented by Chemical Formula 1 and a heterocyclic compound represented by Chemical Formula 2, a composition for the organic material layer of the organic light emitting device, and a method for manufacturing the organic light emitting device.

A substituted thiazole aromatic ring compound and a preparation method therefor, a herbicidal composition and use thereof. The substituted thiazole aromatic ring compound is as shown in general formula I:

##STR00001##

Wherein, Y represents halogen, halogenated alkyl, cyano, nitro or amino; Q represents

##STR00002##

M represents CH or N; X represents

##STR00003##

X.sub.1 represents O or S; X.sub.2 represents OX.sub.3, SX.sub.3 or N(X.sub.3).sub.2. The compound has excellent herbicidal activity against gramineous weeds, broadleaf weeds, and so on even at low application rates, and has high selectivity for crops.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.